MCID: SPN225
MIFTS: 61

Spondyloarthropathy 1

Categories: Genetic diseases, Rare diseases, Bone diseases

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 54 71 38
Ankylosing Spondylitis 38 12 50 25 71 29 41 14 69
Bechterew Syndrome 50 24 71
Spondylarthritis Ankylopoietica 25 71
Marie-Strumpell Spondylitis 50 71
Spondylitis, Ankylosing 25 42
Reiter Syndrome 71 69
Ankylosing Spondylitis, Susceptibility to 24
Spondyloarthropathy, Susceptibility to, 1 13
Spondyloarthropathy 1, Susceptibility to 24
Ankylosing Spondylitis Risk Factor 24
Spondyloarthritis Ankylopoietica 25
Ankylosing Spondyloarthritis 50
Ankylosing Spondylarthritis 71
Marie-Strumpel Spondylitis 24
Spondylitis Ankylopoietica 25
Marie-Struempell Disease 25
Marie-Strumpell Disease 12
Rheumatoid Spondylitis 71
Spondylitis Ankylosans 71
Spondylitis Ankylosing 52
Spondylarthropathies 69
Arthritis, Psoriatic 69
Psoriatic Arthritis 71
Bekhterev's Disease 12
Arthritis, Reactive 69
Reactive Arthritis 71
Bekhterev Syndrome 12
Bechterew Disease 25
Spda1 71
As 25

Characteristics:

OMIM:

54
Inheritance:
multifactorial

Miscellaneous:
overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


HPO:

32
spondyloarthropathy 1:
Inheritance heterogeneous multifactorial inheritance


Classifications:



Summaries for Spondyloarthropathy 1

MedlinePlus : 41 ankylosing spondylitis is a type of arthritis of the spine. it causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. in some people, it can affect other joints. as is more common and more severe in men. it often runs in families. the cause is unknown, but it is likely that both genes and factors in the environment play a role. early symptoms of as include back pain and stiffness. these problems often start in late adolescence or early adulthood. over time, as can fuse your vertebrae together, limiting movement. some people have symptoms that come and go. others have severe, ongoing pain. a diagnosis of as is based on your medical history and a physical examination. you may also have imaging or blood tests. as has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. eating a healthy diet, not smoking, and exercising can also help. in rare cases, you may need surgery to straighten the spine. nih: national institute of arthritis and musculoskeletal and skin disease

MalaCards based summary : Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to osteochondrosis and uveitis, and has symptoms including kyphosis, back pain and arrhythmia. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Etanercept and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

NIH Rare Diseases : 50 ankylosing spondylitis (as) is a type of chronic, inflammatory arthritis that mainly affects the spine. it usually begins with inflammation of the joints between the pelvic bones and spine, gradually spreading to the joints between the vertebrae. signs and symptoms usually begin in adolescence or early adulthood and may include back pain and stiffness. back movement gradually becomes more limited as the vertebrae fuse together. the condition may also affect the shoulders; ribs; hips; knees; and feet; as well as the eyes; bowel; and very rarely, the heart and lungs. as is likely caused by a combination of genetic and environmental factors; variations in several genes are thought to affect the risk to develop as. in most cases, treatment involves exercise and medications to relieve pain and inflammation. last updated: 2/9/2015

UniProtKB/Swiss-Prot : 71 Spondyloarthropathy 1: A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

Genetics Home Reference : 25 Ankylosing spondylitis is a form of ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine. This condition is characterized by back pain and stiffness that typically appear in adolescence or early adulthood. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis.

OMIM : 54
Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300)

Disease Ontology : 12 A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 3 Spondyloarthropathy 1
Spondyloarthropathy 2 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
id Related Disease Score Top Affiliating Genes
1 osteochondrosis 31.3 CRP MMP3 TNF TNFRSF11B TNFSF11
2 uveitis 30.5 CD40LG CD79A TNF
3 lymphoma 30.1 CD40LG CD79A IL17A TNF
4 acral lentiginous melanoma 30.0 CD40LG CD79A HLA-B TNF
5 tularemia 29.7 CD40LG CD79A MRAP TNF
6 neuropathy 29.3 TNF TNFRSF11B TNFSF11
7 systemic lupus erythematosus 29.3 CD40LG CD79A CRP IL17A TNF TNFRSF1B
8 cryptococcosis 28.9 CD40LG HLA-B IL17A MRAP TNF TNFRSF1B
9 discitis 28.6 CD40LG CD79A MRAP TNF TNFRSF1A TNFRSF1B
10 atherosclerosis 27.4 ANKH IL17A IL1RN MMP3 NOD2 TNF
11 rheumatoid arthritis 26.0 CD40LG CD79A CRP HLA-B IL17A IL1RN
12 psoriatic arthritis 12.7
13 smoking as a quantitative trait locus 1 11.8
14 smoking as a quantitative trait locus 2 11.8
15 arthritis 11.6
16 psoriasis 11.6
17 angelman syndrome 11.5
18 antisynthetase syndrome 11.2
19 psoriatic juvenile idiopathic arthritis 11.2
20 hepatocellular carcinoma 11.1
21 systemic onset juvenile idiopathic arthritis 11.1
22 aortic valve disease 2 11.1
23 lip cancer 11.1
24 migraine with brainstem aura 10.8 HLA-B TNF
25 cardiac sarcoidosis 10.8 TNF TNFRSF1B
26 alcoholic neuropathy 10.8 CD40LG CD79A
27 calloso-genital dysplasia 10.8 CD40LG CD79A
28 variola major 10.8 CD40LG CD79A
29 mu chain disease 10.8 CD40LG CD79A
30 rabies 10.8 CD40LG CD79A
31 familial retinoblastoma 10.8 CD40LG CD79A
32 anti-basement membrane glomerulonephritis 10.8 CD40LG CD79A
33 microinvasive cervical squamous cell carcinoma 10.8 CD40LG CD79A
34 fetal erythroblastosis 10.8 CD40LG CD79A
35 spinal canal and spinal cord meningioma 10.8 CD40LG CD79A
36 trichostrongyloidiasis 10.8 CD40LG CD79A
37 leukodystrophy 10.8 CD40LG CD79A
38 retinal microaneurysm 10.8 CD40LG CD79A
39 diphtheritic cystitis 10.8 CD79A CRP
40 heart septal defect 10.8 CD40LG CD79A
41 cryptorchidism arachnodactyly mental retardation 10.8 CD40LG CD79A
42 breast cancer 10.8
43 acute kidney tubular necrosis 10.8 CD40LG CD79A
44 secretory meningioma 10.8 CD40LG CD79A
45 hodgkin's lymphoma, nodular sclerosis 10.8 CD40LG CD79A
46 imperforate oropharynx-costo vetebral anomalies 10.7 CD40LG CD79A
47 acute gonococcal salpingitis 10.7
48 lung cancer susceptibility 2 10.7
49 mucopolysaccharidosis is 10.7
50 lens-induced iridocyclitis 10.7 HLA-B MRAP

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:



Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Symptoms via clinical synopsis from OMIM:

54

Cardiovascular- Heart:
aortic insufficiency
cardiac conduction abnormalities
aortitis

Abdomen- Gastroin testinal:
inflammatory bowel disease (crohns disease and ulcerative colitis)

Skeletal- Pelvis:
arthritis (hip)

Skin Nails & Hair- Skin:
psoriasis

Head And Neck- Eyes:
anterior uveitis

Skeletal- Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
sacroiliitis
more
Skeletal- Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Laboratory- Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative


Clinical features from OMIM:

106300

Human phenotypes related to Spondyloarthropathy 1:

32 (show all 9)
id Description HPO Frequency HPO Source Accession
1 kyphosis 32 HP:0002808
2 back pain 32 HP:0003418
3 arrhythmia 32 HP:0011675
4 aortic regurgitation 32 HP:0001659
5 anterior uveitis 32 HP:0012122
6 hip osteoarthritis 32 HP:0008843
7 psoriasiform dermatitis 32 HP:0003765
8 inflammation of the large intestine 32 HP:0002037
9 enthesitis 32 HP:0100686

UMLS symptoms related to Spondyloarthropathy 1:


back pain, muscle cramp, sciatica

GenomeRNAi Phenotypes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNF TNFRSF11B CD40LG TNFRSF1A IL17A TNFRSF1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TNF TNFRSF11B CD40LG TNFRSF1A IL17A TNFRSF1B
3 Increased shRNA abundance GR00327-A 9.35 BGLAP CD79A HLA-B IL1RN MMP3

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 TNFRSF1B TNFSF11 ANKH CD40LG CD79A IL17A
2 homeostasis/metabolism MP:0005376 9.93 ANKH CD40LG CD79A CRP IL17A IL1RN
3 craniofacial MP:0005382 9.87 TNFRSF1A TNFRSF1B ANKH IL17A TNF TNFRSF11B
4 immune system MP:0005387 9.8 ANKH CD40LG CD79A CRP IL17A IL1RN
5 skeleton MP:0005390 9.36 ANKH CD40LG IL17A IL1RN MMP3 NOD2

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
2
Methotrexate Approved Phase 4,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
3
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Infliximab Approved Phase 4,Phase 3,Phase 1 170277-31-3
6
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1 59-30-3 6037
8
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1 58-05-9 143 6006
9 Vaccines Phase 4,Phase 2
10 Adrenocorticotropic Hormone Phase 4
11 beta-endorphin Phase 4
12 Hormone Antagonists Phase 4,Phase 2,Phase 1
13 Hormones Phase 4,Phase 2,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
15 Melanocyte-Stimulating Hormones Phase 4
16 Analgesics Phase 4,Phase 3,Phase 2,Early Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Early Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
25 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
27 Anticholesteremic Agents Phase 4
28 Antimetabolites Phase 4,Phase 3,Phase 1
29 Cholestyramine Resin Phase 4
30 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1
36 Folic Acid Antagonists Phase 4,Phase 3,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1
38 Vitamin B Complex Phase 4,Phase 3,Phase 1
39 Antibodies, Anti-Idiotypic Phase 4
40 Folate Nutraceutical Phase 4,Phase 3,Phase 1
41 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1
42
Sulfasalazine Approved Phase 3,Phase 2,Phase 1 599-79-1 5353980 5359476
43
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
44
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
45
Hydroxychloroquine Approved Phase 3 118-42-3 3652
46
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
47
Tofacitinib Approved, Investigational Phase 3,Phase 2 477600-75-2
48
Etoricoxib Approved, Investigational Phase 3,Phase 2 202409-33-4 123619
49
Misoprostol Approved Phase 3 59122-46-2 5282381
50
Ustekinumab Approved, Investigational Phase 3,Phase 2 815610-63-0

Interventional clinical trials:

(show top 50) (show all 209)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
3 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
4 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
5 A Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 etanercept;etanercept (half dose);placebo
6 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
7 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Completed NCT00715091 Phase 4 diclophenac;diclophenac
8 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
9 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
10 A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics Completed NCT02470481 Phase 4
11 Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed NCT01212653 Phase 4 Simponi
12 Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis Completed NCT00544557 Phase 4 Etanercept
13 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
14 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
15 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
16 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Recruiting NCT03020992 Phase 4 Certolizumab Pegol
17 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Recruiting NCT02897115 Phase 4
18 Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Recruiting NCT02509026 Phase 4
19 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Recruiting NCT03151551 Phase 4 Ixekizumab;Adalimumab
20 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Recruiting NCT02798211 Phase 4 Secukinumab;Secukinumab
21 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation Recruiting NCT02814175 Phase 4 methotrexate (MTX)
22 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038) Not yet recruiting NCT03253796 Phase 4
23 Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics Terminated NCT01971918 Phase 4
24 Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis Terminated NCT00726804 Phase 4 Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
25 Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients Terminated NCT00910273 Phase 4 etanercept
26 Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease Withdrawn NCT00972218 Phase 4
27 Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria Unknown status NCT01426815 Phase 3 Placebo;Golimumab
28 Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Completed NCT00844805 Phase 3 Infliximab;Placebo;Naproxen
29 Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) Completed NCT01453725 Phase 3
30 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis Completed NCT01358175 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo
31 Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis Completed NCT01087762 Phase 3
32 Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes Completed NCT01258738 Phase 3 Background NSAID;Background NSAID
33 Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain Completed NCT01040195 Phase 3 Methotrexate, Hydroxychloroquine;Placebo
34 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Completed NCT01064856 Phase 3
35 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Completed NCT01392326 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo Comparator
36 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01172938 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
37 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed NCT01877668 Phase 3 Tofacitinib 5 mg BID;Tofacitinib 10 mg BID;Adalimumab;Placebo;Placebo
38 MYL-1401A Efficacy and Safety Comparability Study to Humira® Completed NCT02714322 Phase 3
39 A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis Completed NCT00764686 Phase 3
40 Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Completed NCT00367237 Phase 3 Infliximab + methotrexate (IFX + MTX);Methotrexate (MTX)
41 A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) Completed NCT01208207 Phase 3 Part I - etoricoxib 60 mg;Part I - etoricoxib 90 mg;Part I- naproxen 1000 mg;Part I - Placebo to naproxen 500 mg;Part II- etoricoxib 60 mg;Part II- etoricoxib 90 mg;Part II- naproxen 1000 mg;Part I - Placebo to etoricoxib 60 mg;Part I - Placebo to etoricoxib 90 mg;Part II- Placebo to etoricoxib 60 mg;Part II - Placebo to etoricoxib 90 mg;Part II- Placebo to naproxen 500 mg
42 A Study of Golimumab in Participants With Active Psoriatic Arthritis Completed NCT02181673 Phase 3 Placebo;Golimumab
43 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed NCT01882439 Phase 3 Tofacitinib;Tofacitinib;Tofacitinib;Tofacitinib
44 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Completed NCT01087788 Phase 3
45 Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) Completed NCT00202865 Phase 3
46 PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity Completed NCT00576706 Phase 3 Rebamipide;Misoprostol
47 Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis Completed NCT00085644 Phase 3
48 Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis Completed NCT00421915 Phase 3 Enbrel (etanercept)
49 A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Recruiting NCT03129100 Phase 3 Ixekizumab;Placebo
50 A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Recruiting NCT02757352 Phase 3 Ixekizumab;Placebo

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

id Genetic test Affiliating Genes
1 Ankylosing Spondylitis 29
2 Spondyloarthropathy 1, Susceptibility to 24

Anatomical Context for Spondyloarthropathy 1

MalaCards organs/tissues related to Spondyloarthropathy 1:

39
Bone, Testes, Heart, Lung, Skin, Eye, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
id Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B, HLA-B27 undetermined variant risk factor

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CD40LG CD79A CRP HLA-B IL17A IL1RN
2
Show member pathways
13.01 CD40LG HLA-B IL17A IL1RN MMP3 NOD2
3
Show member pathways
12.77 CD40LG HLA-B IL17A TAPBP TNF
4
Show member pathways
12.55 CD40LG CD79A TNF TNFRSF1A TNFRSF1B
5
Show member pathways
12.52 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
6 12.17 CD40LG TNFRSF1A TNFRSF1B TNFSF11
7 12.05 CD40LG CD79A IL17A IL1RN TNF TNFRSF1A
8 11.98 TNF TNFRSF11B TNFRSF1A TNFSF11
9 11.91 IL17A MMP3 TNF TNFRSF1B
10 11.8 CD40LG TNF TNFRSF1A TNFSF11
11 11.8 MMP3 NOD2 TNF TNFRSF1A TNFRSF1B
12 11.75 IL17A MMP3 TNF TNFSF11
13 11.64 TNF TNFRSF1A TNFRSF1B
14
Show member pathways
11.56 CD40LG MMP3 TNF TNFRSF1A
15
Show member pathways
11.52 CD40LG TNF TNFRSF1A TNFRSF1B TNFSF11
16 11.51 TNF TNFRSF1A TNFRSF1B
17
Show member pathways
11.47 TNF TNFRSF1A TNFRSF1B
18 11.42 IL1RN TNF TNFRSF1A TNFRSF1B
19
Show member pathways
11.36 TNF TNFRSF1A TNFRSF1B
20 11.36 BGLAP TNF TNFRSF11B TNFSF11
21 11.26 CD40LG TNFRSF1A TNFRSF1B
22 11.24 TNF TNFRSF1A TNFRSF1B
23 11.15 CD40LG IL17A TNF TNFSF11
24 11.07 NOD2 TNF TNFRSF1A
25
Show member pathways
11.03 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
26 10.84 TNFRSF11B TNFSF11
27 10.8 BGLAP TNFRSF11B TNFSF11

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.81 ANKH CD40LG CD79A HLA-B TNF TNFRSF11B
2 cell surface GO:0009986 9.8 CD40LG HLA-B NOD2 TNF TNFRSF1A
3 extracellular region GO:0005576 9.7 BGLAP CD40LG CRP IL17A IL1RN MMP3
4 external side of plasma membrane GO:0009897 9.67 CD40LG CD79A IL17A TNF
5 membrane raft GO:0045121 9.62 CD79A TNF TNFRSF1A TNFRSF1B
6 extracellular space GO:0005615 9.32 BGLAP CD40LG CRP IL17A IL1RN MMP3
7 plasma membrane GO:0005886 10.03 ANKH CD40LG CD79A HLA-B IL1RN MRAP

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.86 TNF TNFRSF11B TNFRSF1A TNFRSF1B
2 apoptotic signaling pathway GO:0097190 9.74 TNF TNFRSF11B TNFRSF1B
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.71 NOD2 TNF TNFRSF1A TNFSF11
4 positive regulation of JNK cascade GO:0046330 9.7 NOD2 TNF TNFSF11
5 response to glucocorticoid GO:0051384 9.69 BGLAP IL1RN TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 CD40LG NOD2 TNF TNFSF11
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.63 TNF TNFRSF1A TNFRSF1B
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.63 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
9 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 TNF TNFRSF1B
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.58 IL17A NOD2
11 response to inorganic substance GO:0010035 9.58 BGLAP TNFRSF11B
12 inflammatory response GO:0006954 9.56 CD40LG CRP IL17A IL1RN TNF TNFRSF11B
13 negative regulation of lipid storage GO:0010888 9.55 CRP TNF
14 positive regulation of ceramide biosynthetic process GO:2000304 9.54 TNF TNFRSF1A
15 positive regulation of osteoclast differentiation GO:0045672 9.5 IL17A TNF TNFSF11
16 death-inducing signaling complex assembly GO:0071550 9.49 TNF TNFRSF1A
17 regulation of establishment of endothelial barrier GO:1903140 9.48 TNF TNFRSF1A
18 regulation of immunoglobulin secretion GO:0051023 9.43 CD40LG TNF
19 regulation of osteoclast differentiation GO:0045670 9.43 BGLAP TNF TNFSF11
20 immune response GO:0006955 9.32 CD40LG HLA-B IL17A IL1RN TAPBP TNF

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.33 CD40LG TNF TNFSF11
2 tumor necrosis factor-activated receptor activity GO:0005031 9.13 TNFRSF11B TNFRSF1A TNFRSF1B
3 cytokine activity GO:0005125 9.1 CD40LG IL17A IL1RN TNF TNFRSF11B TNFSF11

Sources for Spondyloarthropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....